196 related articles for article (PubMed ID: 19769081)
1. [New antiretroviral drug classes in HIV therapy].
Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
[No Abstract] [Full Text] [Related]
2. Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
[No Abstract] [Full Text] [Related]
3. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
[TBL] [Abstract][Full Text] [Related]
4. Two new drugs for HIV infection.
Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
[No Abstract] [Full Text] [Related]
5. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
6. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
Horster S; Goebel FD
Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
[No Abstract] [Full Text] [Related]
7. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Arribas JR
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV agents. New drugs--hope and a degree of caution.
TreatmentUpdate; 2007; 19(6):9-10. PubMed ID: 18041153
[No Abstract] [Full Text] [Related]
10. [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Moreno Cuerda VJ; Rubio García R; Barros Aguado C; Morales Conejo M
Rev Clin Esp; 2008 Oct; 208(9):463-6. PubMed ID: 19000475
[TBL] [Abstract][Full Text] [Related]
11. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV agents. New drugs, new hope, old lessons.
TreatmentUpdate; 2007 Feb; 19(2):1-3. PubMed ID: 17447311
[No Abstract] [Full Text] [Related]
15. [Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].
Katanaga H
Nihon Naika Gakkai Zasshi; 2009 Nov; 98(11):2802-8. PubMed ID: 22462133
[No Abstract] [Full Text] [Related]
16. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
18. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
[No Abstract] [Full Text] [Related]
19. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
20. New drugs.
Pozniak A
J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271
[No Abstract] [Full Text] [Related]
[Next] [New Search]
